Immunovant: Piper Sandler cuts target price to $50 from $66
IMVT•Piper Sandler cut its target price for Immunovant to $50 from $66.
Related News
Barings BDC files initial beneficial ownership statement for Vice President William Woody Harrison
BBDC•
Procter & Gamble CFO Andre Schulten reports sale of $5.18 million in common shares
PG•
Palo Alto Networks says AI accelerates cyberattacks on digital supply chains
PANW•
American Tower files for three-part senior notes; size not disclosed
AMT•
US FDA orders new eye risk warnings for Ozempic, Zepbound
LLY•